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ABSTRACT
Objective: To accurately define venous
thromboembolism (VTE) in the routinely collected
Swedish health registers and quantify its incidence in
and around pregnancy.
Study design: Cohort study using data from the
Swedish Medical Birth Registry (MBR) linked to the
National Patient Registry (NPR) and the Swedish
Prescribed Drug Register (PDR).
Setting: Secondary care centres, Sweden.
Participant: 509 198 women aged 15–44 years who
had one or more pregnancies resulting in a live birth or
stillbirth between 2005 and 2011.
Main outcome measure: To estimate the incidence
rate (IR) of VTE in and around pregnancy using
various VTE definitions allowing direct comparison
with other countries.
Results: The rate of VTE varied based on the VTE
definition. We found that 43% of cases first recorded
as outpatient were not accompanied by anticoagulant
prescriptions, whereas this proportion was much lower
than those cases first recorded in the inpatient register
(9%). Using our most inclusive VTE definition, we
observed higher rates of VTE compared with previously
published data using similar methodology. These
reduced by 31% (IR=142/100 000 person-years; 95%
CI 132 to 153) and 22% (IR=331/100 000 person-
years; 95% CI 304 to 361) during the antepartum and
postpartum periods, respectively, using a restrictive
VTE definition that required anticoagulant prescriptions
associated with diagnosis, which were more in line
with the existing literature.
Conclusions: We found that including VTE codes
without treatment confirmation risks the inclusion of
false-positive cases. When defining VTE using the
NPR, anticoagulant prescription information should
therefore be considered particularly for cases recorded
in an outpatient setting.
INTRODUCTION
Venous thromboembolism (VTE) is a serious
and potentially fatal condition with an inci-
dence of 1–3 per 1000 per year.1 Owing to its
rarity, the use of large administrative health-
care data sets is a very cost-effective way to
study the epidemiology of VTE in terms of
incidence and identiﬁcation of risk factors.
While routinely collected administrative
registry data have the advantage of being
large, prospectively recorded, population
based and with minimal selection or recall
bias, ensuring their accuracy in diagnosis is
paramount for the veracity of ﬁndings of
studies using these data.
The Swedish National Patient Register
(NPR) was established in 1964 with complete
national coverage from 1987 onwards. To
date, various validation studies have been
conducted to ensure the quality of data for a
wide range of acute and chronic conditions.
For instance, a review of NPR validation
studies conducted by Ludvigsson et al2
Strengths and limitations of this study
▪ We analysed more than 680 000 pregnancies to
assess the robustness of the venous thrombo-
embolism (VTE) diagnosis recorded in the
Swedish National Patient Register using anti-
coagulant prescriptions in a way which has not
been done before using these data.
▪ The use of recent data from the national regis-
tries makes our study findings contemporary and
generalisable to the majority of women of child-
bearing age.
▪ Our VTE algorithm confirmation relies principally
on anticoagulant prescriptions and we were not
able to carry out any sort of external validation.
However, our absolute rates of VTE in and
around pregnancy are in line with the existing
literature.
▪ We may have incorrectly confirmed VTE cases
for some women who were being prescribed low
molecular weight heparin as thromboprophylaxis
rather than therapy which we cannot accurately
differentiate from registry data.
Abdul Sultan A, et al. BMJ Open 2015;5:e008864. doi:10.1136/bmjopen-2015-008864 1
Open Access Research
concluded that the positive predictive value (PPV) varies
based on the diagnosis but generally ranges between
85% and 95%. However, it is noteworthy that the previ-
ous validation studies were only based on inpatient cases
(those admitted) and did not speciﬁcally validate the
outcome of VTE. The recent inclusion of the Swedish
outpatient data (those presenting to hospital but not
admitted) from 2001 onwards and the availability of
linked data from the Prescribed Drug Register (PDR)
now allows for the assessment of different deﬁnitions of
VTE to determine the one most appropriate for use in
epidemiological studies.3
A particular setting in which VTE has been commonly
studied is in and around pregnancy as, although rare,
VTE is one of the leading causes of maternal mortality
in developed countries.4 Our previous work using
England’s linked primary and secondary healthcare data
has shown that the rate of VTE in and around preg-
nancy varies markedly depending on the data source
and VTE deﬁnition used.5 A separate VTE validation
study among pregnant women from Denmark6 reported
the overall PPV to be 75% for inpatient cases but a
much lower PPV (31%) for those only presenting to the
emergency department. Similarly, Virkus et al7 in their
study reported that 35% of women who received a diag-
nosis of VTE in the Danish NPR during pregnancy/post-
partum were not validated (ie, they were false-positives).
The need to identify a robust deﬁnition of VTE for
use in epidemiological studies is clear. Studying this rare
event in and around pregnancy gives us the ability to dir-
ectly compare estimates of incidence arising from the
Swedish data with those from other countries where val-
idation of deﬁnitions has previously been undertaken.
The aim of our study was to use the Swedish NPR to
determine the incidence rate of VTE in and around
pregnancy using various VTE deﬁnitions and compare
these with rates from other countries and healthcare
settings.
METHOD
Data source
The Swedish Medical Birth Registry (MBR) was estab-
lished in 1973 and collects information on antenatal
and perinatal factors (eg, gestational length, mode of
delivery) and their impact on the health of the mother
and infant. The registry was standardised and compu-
terised from 1982 onwards.8 It contains information on
birth and delivery records from across Sweden with the
addition of 100 000 births each year. Apart from delivery
and birth information, the MBR also contains up to 12
diagnoses which may occur during pregnancy or in the
course of the women’s stay in the delivery unit. These
are coded using the International Classiﬁcation of
Diseases (ICD) codes. The MBR has been subjected to
numerous quality checks in the past and the data
recorded are of a high standard.8 9 The personal iden-
tity number assigned to each resident in Sweden allows
merging of data between registries such as the NPR and
PDR at an individual level.10 The NPR initially only
included the information on hospitalised patients
(inpatient data); however, since 2001, it also includes
outpatient consultations (outpatient data). The data
contained within the NPR can mainly be categorised as
patient-related data (eg, personal identity number, sex),
administrative data (eg, visit date, admission and dis-
charge dates) and medical data (eg, diagnosis and pro-
cedure information). Each diagnosis recorded within
the NPR may be categorised as either a primary or sec-
ondary diagnosis. The primary diagnosis should be the
main condition that was treated or investigated at the
end of a hospital episode, whereas the secondary diag-
nosis may or may not be directly relevant to the primary
diagnosis. Finally, ﬁlled drug prescriptions are recorded
in PDR with the date of dispensing, drug name, strength
and preparation according to the Anatomical
Therapeutic Chemical (ATC) classiﬁcation.11
Study population
For the purpose of this study, we included all women
aged 15–44 years from the MBR who experienced a
pregnancy between 1 July 2005 and 31 December 2011.
Using data from 2005 allowed us to obtain prescription
data for all of our study population.
Defining venous thromboembolism
Initially, our working VTE deﬁnition included all cases
of VTE recorded in either the NPR (inpatient/out-
patient) or MBR occurring at any time women were
between 15 and 44 years of age, while pregnant or not.
We used the relevant ICD, Tenth Revision (ICD-10)
codes (as previously used,5 online supplementary table
S1) to identify VTE diagnosis regardless of its hierarch-
ical position in the diagnostic ﬁeld (primary or second-
ary). These were then stratiﬁed by the source where the
ﬁrst VTE case was identiﬁed (inpatient vs outpatient
data). All VTEs identiﬁed in the birth registry were cate-
gorised as inpatient VTEs. For the purpose of this study,
we only included the ﬁrst recorded VTE and therefore
excluded all subsequent VTE diagnoses. Since the com-
plete NPR coverage dates back to 1987, we also used the
relevant ICD-9 codes (415, 451, 452, 453, 671 or 673) to
exclude anyone with VTE prior to their entry into the
study period. For all women with ﬁrst VTE, we extracted
information on anticoagulant therapy along with infor-
mation on date and cause of death from the cause of
death register, if the woman died within the study
period.
Algorithm confirmation
AVTE code was considered to be algorithm conﬁrmed if
it was accompanied by an anticoagulant prescription
(based on ATC codes; online supplementary table S2)
within 90 days of the event or if the woman died within
30 days of the event and the underlying cause of death
was VTE. This VTE deﬁnition has been validated
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previously in English healthcare data with a PPV of
84%.12 On the basis of the above information, we con-
sidered two VTE deﬁnitions.
VTE deﬁnition A: Any ﬁrst VTE recorded in either
inpatient or outpatient records regardless of algorithm
conﬁrmation.
VTE deﬁnition B: A ﬁrst VTE event recorded as an
inpatient or outpatient that was conﬁrmed by our algo-
rithm. As such, deﬁnition B consists of cases that are a
subset of deﬁnition A.
Defining exposure time
Women’s follow-up time between age 15–44 years was
divided into time associated with pregnancy (deﬁned
from the date of conception based on a woman’s gesta-
tional age until 12 weeks postpartum for each and every
pregnancy identiﬁed) and ‘time outside pregnancy’ (all
other available follow-up times as described previously).5
Time associated with pregnancy was subsequently split
into antepartum and postpartum time. In order to min-
imise the potential misclassiﬁcation5 between antepar-
tum and postpartum events, a third category of ‘time
around delivery’ was also considered. Therefore, the
time associated with pregnancy was divided into the
antepartum period (from the estimated date of concep-
tion until 2 days before the date of delivery), time
around delivery (1 day before until 2 days after delivery)
and the postpartum period, which was deﬁned from
3 days after delivery until 12 weeks postpartum.
Postpartum time was then further split into early post-
partum (up to 6 weeks after delivery) and late post-
partum (7–12 weeks after delivery).
Statistical analysis
We calculated the frequency and proportion of ﬁrst
identiﬁed VTE stratiﬁed by whether it was registered as
an inpatient or outpatient visit. For each VTE deﬁnition,
we calculated the rate of VTE per 100 000 person-years
in and around pregnancy separately. We compared our
absolute rate of VTE from each VTE deﬁnition during
speciﬁc antepartum and postpartum periods with other
similar studies from England5 and Denmark.13 The VTE
incidence estimates in the English data were derived
from a proportion of the English representative popula-
tion. The diagnosis of VTE, whether they ﬁrst presented
as a hospital admission or in primary care, was con-
ﬁrmed using the same algorithm as used in the present
study. The Danish VTE estimates were derived from the
Danish NPR13 where the diagnosis of VTE recorded in
the hospital discharge data had been previously vali-
dated in a small subset of the data. Finally, we compared
the rate of VTE during the antepartum and postpartum
periods to time outside pregnancy using a Poisson
regression model to calculate incidence rate ratios (IRR)
adjusted for age and calendar year. All analyses were per-
formed using Stata V.12, Stata Corp., College Station,
Texas, USA. This study was approved by the ethical
review board.
RESULTS
Study population
Our cohort consisted of 509 198 women who experi-
enced at least one pregnancy resulting in a live birth or
a stillbirth during the study period. Of the 681 756 preg-
nancies analysed, 2389 (0.4%) ended in a stillbirth. Our
person-years of follow-up associated with different time
periods of pregnancy and outside pregnancy are sum-
marised in table 1.
Confirmation of VTE cases
We identiﬁed a total of 2864 patients with ﬁrst incident
diagnosis of VTE from 2005, 1789 (62%) of which were
ﬁrst recorded at an outpatient visit (ﬁgure 1). We
observed that 91% of VTEs ﬁrst recorded during the
inpatient visit were algorithm conﬁrmed compared with
57% for those recorded as an outpatient. Of the total of
2000 patients with validated VTEs, 46% (n=928) received
heparin/low-molecular-weight heparin (LMWH) within
90 days of the event, whereas 54% were prescribed war-
farin (mostly during the postpartum period and time
outside pregnancy). When comparing VTE cases
between data sources, we found that 22% (n=627) of the
patients with VTE had a diagnosis recorded both in
inpatient and outpatient data within 90 days of the
initial event with 20% (n=569) and 58% (n=1668) solely
recorded in inpatient and outpatient data, respectively.
Conﬁrmation of VTE cases based on VTE type and pos-
ition of diagnosis (primary vs secondary) is presented as
online supplementary table S3. Of 757 cases of non-
speciﬁc thrombophlebitis diagnoses, 25% (n=190) had
evidence of hirudoid (C05BA01) prescriptions within
90 days of the event of which 44% (n=83) were con-
ﬁrmed based on our algorithm.
Absolute rate of VTE in and around pregnancy using
various VTE definitions
Using VTE deﬁnition A (any recording of VTE without
conﬁrmation), we found the absolute rate of VTE
Table 1 Basic characteristics of the study population
Variable N (%)
Total number of women aged 15–44 509 198
Total number of pregnancies 681 756
Median follow-up 6.5 years
Person-years of follow-up
Outside pregnancy 2 625 033
Antepartum 486 170
Around delivery 7438
Postpartum 153 465
First VTE type (n=VTE events)
Pulmonary embolism 678 (24)
Deep vein thrombosis 2186 (76)
Birth outcome (n=pregnancies)
Live birth 681 756 (99.6)
Stillbirth 2389 (0.4)
All figures are number (%) unless otherwise specified.
VTE, venous thromboembolism.
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during the time outside pregnancy to be 42 per 100 000
person-years (table 2). This rate decreased to 38 per
100 000 person-years when we used our restricted VTE
deﬁnition (VTE deﬁnition B). Figure 2 shows the rate of
VTE by weeks of postpartum which shows variation
during the ﬁrst 3 weeks postpartum based on the VTE
deﬁnition. The rates of VTE during speciﬁc antepartum
and postpartum periods using VTE deﬁnition A were
much higher than in previous studies using the Danish
and English data with no overlapping CIs except for the
time around delivery and the late postpartum period.
However, the absolute rates using VTE deﬁnition B
during the third trimester of antepartum, postpartum
period and time outside pregnancy were broadly in line
with the Danish and/or English data with overlapping
CIs.
IRR of VTE in and around pregnancy compared with time
outside pregnancy
Using VTE deﬁnition A, we found a 5-fold (IRR=5.08;
95% CI 4.66 to 5.54) and 10-fold (IRR=10.2; 95% CI
9.27 to 11.25) higher rate of VTE during the antepar-
tum and postpartum periods, respectively, compared
with time outside pregnancy (table 3). Compared with
time outside pregnancy, the overall IRRs during the
antepartum (IRR=3.80) and postpartum (IRR=8.72)
periods using deﬁnition B were very similar to the
English data (IRR=3.10 and 8.54, respectively). In con-
trast, using VTE deﬁnition B in the Swedish data gave a
statistically signiﬁcant increased risk of VTE during the
ﬁrst trimester, which was not seen in the English or
Danish data.
DISCUSSION
Main finding
Using a nationwide cohort of pregnant women, we have
shown that the majority of ﬁrst VTEs recorded in the
Swedish inpatient data (91%) were accompanied by anti-
coagulant therapy following the event. This proportion,
however, was much lower for those ﬁrst recorded as out-
patients. We also found that the rate of VTE in and
around pregnancy and outside pregnancy varied based
on the VTE deﬁnition used. Our most inclusive VTE def-
inition (VTE deﬁnition A) gave us absolute rates of VTE
in and around pregnancy which were much higher com-
pared with those obtained from the English and Danish
data. However, using a more restrictive deﬁnition of VTE
Figure 1 Flow diagram of the first recorded venous thromboembolism (VTE) using the inpatient and outpatient register.
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which largely relied on conﬁrmation of VTE cases based
on anticoagulant therapy from the prescription register,
we found absolute and relative rates of VTE to be more
comparable with the English and/or Danish data which
used similar deﬁnitions.
Strength and limitations
Using Swedish national registries, we analysed more
than 680 000 pregnancies resulting in a live birth or
stillbirth to determine how the incidence of VTE in
and around pregnancy varies based on the VTE deﬁn-
ition and data set used. The ability to combine national
data from inpatient, outpatient, birth and prescription
registers allowed us to directly assess the robustness of
the VTE diagnosis occurring in different data sources
in a way which has not been done before using
these data. Furthermore, the use of recent data from
the national registries makes our study ﬁndings con-
temporary and generalisable to the majority of women
of childbearing age.
Table 2 Absolute rate of first VTE per 100 000 person-years in and around pregnancy and outside pregnancy
Time period
VTE definition A
(using any code for
VTE regardless of
confirmation)
VTE definition B
(using only algorithm-
confirmed VTE) English data5 Danish data13
N Rate (95% CI) N Rate (95% CI) N Rate N Rate
Outside pregnancy 1105 42 (40 to 44) 1015 38 1480 32 (30–33) 2895 36 (34–37)
Antepartum 995 205 (192 to 218) 690 142 (132 to 153) 156 99 (85–116) 491 107 (97–116)
Trimester 1 207 136 (118 to 155) 172 113 (97 to 131) 23 46 (31–70) 61 41 (32–52)
Trimester 2 275 174 (154 to 196) 178 112 (97 to 130) 30 58 (41–83) 75 57 (46–72)
Trimester 3 513 292 (268 to 319) 340 194 (174 to 216) 103 182 (150–221) 355 197 (177–219)
Around delivery 115 1546 (1288 to 1856) 79 1061 (851 to 1323) 34 1428 (1020–1998) –
Postpartum 649 423 (392 to 457) 509 331 (304 to 361) 135 274 (231–324) 218 175 (153–200)
Early postpartum 584 754 (696 to 818) 460 593 (541 to 650) 177 468 (391–561) 199 304 (264–350)
Late postpartum 65 85 (70 to 109) 49 64 (49 to 85) 18 73 (46–116) 319 32 (19–50)
Early postpartum (first 6 weeks after delivery).
Late postpartum (6 weeks after delivery).
VTE, venous thromboembolism.
Figure 2 Absolute rate of venous thromboembolism (VTE) per 100 000 person-years in and around pregnancy using different
methods and data sources compared with the English5 and Danish data.13
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For our VTE deﬁnition B, we used an algorithm that
mimics a previously validated VTE deﬁnition in the
UK’s primary care data with a PPV of 84%.12 This deﬁn-
ition, though itself speciﬁcally validated in an outside
pregnancy setting, has been shown to produce absolute
rates of VTE during the antepartum and postpartum
periods which are comparable to pooled estimates from
several countries published in the existing literature.5
While we did not have the data to externally validate
our VTE conﬁrmation algorithm in the Swedish data, a
similar VTE deﬁnition has been externally validated in
the Danish patient register with a PPV of 99%.14 The
study also highlighted that cross-linkage with the
national register of medicinal products provides reliable
validation of the VTE event. It is noteworthy that such
a validation does not give us any indication of the nega-
tive predictive value and we cannot rule out that, par-
ticularly within pregnancy, certain women with VTE
may receive anticoagulant prescription from hospital
immediately following diagnosis not routinely recorded
in the PDR. In this study, however, we believe that the
impact of this will be minimal as women diagnosed
with VTE are likely to be on anticoagulant therapy for
at least 4 weeks, which should therefore be captured in
the PDR.
Another limitation of this study is that our algorithm
conﬁrmation relies principally on anticoagulant pre-
scriptions and we were not able to carry out any sort of
external validation (review of medical records). Second,
our algorithm only examines one dimension of case con-
ﬁrmation. The optimal validation study would examine
speciﬁcity, sensitivity, and positive and negative predictive
values for which no other data sources were available.
However, the absolute rates using VTE deﬁnition B for
antepartum and the early postpartum period of 142 and
593 per 100 000 person-years, respectively, are broadly in
concordance with the pooled estimates5 from previous
studies conducted after 2005 (118 and 424 per 100 000
person-years, respectively) with overlapping CIs.
Comparison with other studies
This study is not a traditional validation study as previ-
ously conducted in other settings,6 7 12 15 (ie, validating
VTE cases by reviewing patients’ medical records).
However, Rosengren et al16 carried out external valid-
ation of VTE cases identiﬁed in a random sample of
men born between 1915 and 1922 and between 1924
and 1925 in a particular Swedish county in their study
to quantify the impact of psychosocial factors on VTE
using NPR. The study found that 85% and 70% of
their inpatient recorded pulmonary embolism (PE)
and deep vein thrombosis (DVT) cases, respectively,
were externally validated. Our algorithm was able to
conﬁrm 94% and 88% of inpatient recorded PE and
DVT cases, respectively, which may be due to changes
in the diagnostic modalities and improvements in the
recording of VTE from 1998 onwards. Our higher and
lower number of cases conﬁrmed in the outpatient and
inpatient, respectively, have also been previously
demonstrated in the Danish data6 where VTE diagnosis
was validated by conducting a manual review of
medical records for each patient. One possible explan-
ation for the lower number of outpatient cases con-
ﬁrmed by our algorithm could be the potential
inclusion of superﬁcial thrombophlebitis treated with
hirudoid. However, only 26% (n=98) of non-conﬁrmed
cases (based on our algorithm) of non-speciﬁc
thrombophlebitis (ICD-10: I809, I821, I808, I803;
ICD-9: 451, 671) recorded in the outpatient were pre-
scribed hirudoid within 90 days of the event. Therefore
it may be possible that those with suspected VTE seen
in the outpatient are erroneously given VTE diagnosis
before case conﬁrmation which may require further
investigation.
We found that, using our restrictive VTE deﬁnition,
our absolute rates of antepartum and postpartum VTE
were 31% and 22% lower, respectively, than VTE without
conﬁrmation (VTE deﬁnition A). This ﬁnding is consist-
ent with another Danish validation study7 which
Table 3 IRR of the rate of VTE using various analysis methods
VTE definition A
IRR* (95%CI)
VTE definition B
IRR* (95%CI)
English data5
IRR (95%CI)†
Danish data13
IRR (95%CI)†Time period
Outside pregnancy Reference
Antepartum 5.08 (4.66 to 5.54) 3.80 (3.44 to 4.19) 3.10 (2.63 to 3.66) 2.95 (2.68 to 3.25)
Trimester 1 3.42 (2.95 to 3.98) 3.04 (2.58 to 3.56) 1.46 (0.96 to 2.20) 1.12 (0.86 to 1.45)
Trimester 2 4.31 (3.78 to 4.93) 3.01 (2.56 to 3.53 1.82 (1.27 to 2.62) 1.58 (1.24 to 1.99)
Trimester 3 7.14 (6.43 to 7.94) 5.12 (4.53 to 5.80) 5.69 (4.66 to 6.95) 5.48 (4.89 to 6.12)
Around delivery 37.5 (30.9 to 44.45) 27.97 (22.24 to 35.17) 44.5 (31.68 to 62.54) –
Postpartum 10.21 (9.27 to 11.25) 8.72 (7.83 to 9.70) 8.54 (7.16 to 10.19) 4.85 (4.21 to 5.57)
Early postpartum 19.27 (16.53 to 20.21) 15.62 (14.00 to 17.45) 14.61 (12.10 to 17.67) 8.44 (7.27 to 9.75)
Late postpartum 2.06 (1.60 to 2.64) 1.69 (1.26 to 2.25) 2.29 (1.44 to 3.65) 0.89 (0.53 to 1.39)
Early postpartum (first 6 weeks after delivery).
Late postpartum (6 weeks after delivery).
*Adjusted for age and calendar year.
†Unadjusted ratio calculated based on the data provided.
IRR, incidence rate ratios; VTE, venous thromboembolism.
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reported that 40% and 21% of the VTE diagnosis
during the antepartum and postpartum periods, respect-
ively, are not validated. We do acknowledge that there
may be differences between the Danish and Swedish reg-
isters in terms of data recording; therefore, the above
comparisons should be interpreted with caution.
Our absolute rates of VTE during the ﬁrst and second
trimesters using VTE deﬁnition A were slightly higher
than those reported by the English and Danish data.
This ﬁnding is supplemented by the lower maternal
VTE-related mortality observed in Sweden17 compared
with England4 and Denmark.18 This may reﬂect better
management/treatment of VTE, particularly during
early pregnancy in Sweden. On that note, we cannot
ignore the fact that there is a possibility that we have
incorrectly included as VTE cases some women who
were being treated with LMWH as preventive thrombo-
prophylaxis rather than as a therapy for a newly occur-
ring VTE event. There is, however, considerable
difﬁculty in knowing the exact dosage of LMWH that a
woman would or should receive for thromboprophylaxis
as this is dependent on a combination of risk factors
and physician judgement which we cannot presume to
infer from registry data. The lower rate of VTE during
the postpartum period in the Danish data might be due
to the potential inclusion of only inpatient VTE cases
(although this is not clearly stated in the study).
However, even with the inclusion of outpatient data, con-
cerns over their coverage and the use of many different
deﬁnitions to record this information within the register
should not be overlooked.19 Finally, our absolute rate of
VTE during the antepartum and postpartum periods
were much higher using VTE deﬁnition A compared
with the previous studies done on the subject using data
up to or after 2005.13 20 21 While our incidence rate of
VTE in and around pregnancy varied based on VTE def-
inition used, our IRR during the antepartum and post-
partum periods compared with time outside pregnancy
remained broadly similar. This, however, needs to be
further investigated for other risk factors which may be
more sensitive to VTE deﬁnition in these data.
Implications
Our study has important implications in the way VTE is
deﬁned in the Swedish NPR. While a higher proportion
of VTEs ﬁrst recorded in the inpatient data are accom-
panied by an anticoagulant prescription, this proportion
was far lower for those ﬁrst recorded in the outpatient
data. If all outpatient cases were to be included in future
research studies, they are likely to include false-positives,
leading to an overestimation of risk if prescription infor-
mation is not used. Our restrictive VTE deﬁnition pro-
vided absolute rates of VTE during the antepartum and
postpartum periods that were more comparable to the
estimates from the previously published English data,
which used similar methodology for case conﬁrmation.
Although this study only assessed women of childbearing
age (15–44 years) and further comparative studies
should be recommended in other patient groups, we
believe it is not unreasonable to suggest that prescrip-
tion conﬁrmation of VTE should be carefully considered
when studying the epidemiology of VTE using the
Swedish health registries.
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